Vin Medicament Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
- Paid Up Capital ₹ 0.30 M
- Company Age 4 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.81 M
- Revenue Growth 13.36%
- Profit Growth 8.71%
- Ebitda 15.15%
- Net Worth 56.85%
- Total Assets 25.43%
About Vin Medicament
Vin Medicament Private Limited (VMPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 June 2020 (Four years and eight months 0 days old ). Its registered office is in Jaipur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.30 M.
The company currently has active open charges totaling ₹0.81 M.
Kamal Grover, Pawan Grover, Kajal, and One other member serve as directors at the Company.
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909RJ2020PTC069226
- Company No.
069226
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jun 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Vin Medicament?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamal Grover  | Director | 23-Jun-2020 | Current |
| Pawan Grover | Director | 23-Jun-2020 | Current |
| Kajal | Director | 23-Jun-2020 | Current |
| Khushbu Grover | Director | 07-Jul-2020 | Current |
Financial Performance of Vin Medicament.
Vin Medicament Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.36% increase. The company also saw a slight improvement in profitability, with a 8.71% increase in profit. The company's net worth Soared by an impressive increase of 56.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vin Medicament?
Unlock access to Vin Medicament's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.81 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.08 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Jun 2022 | Hdfc Bank Limited | ₹0.81 M | Open |
How Many Employees Work at Vin Medicament?
Vin Medicament has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vin Medicament, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vin Medicament's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.